Floatz logo

DYNAMOS

Tuberous Sclerosis Complex (TSC)

GRIN Therapeutics, Inc.Small moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Tuberous Sclerosis Complex (TSC) cohort.

Asset / SponsorPhaseRating
Carbamazepine
GRIN Therapeutics, Inc.
Phase 3BB
Ycj-01 Full Spectrum Cannbis Extract
Oils4Cure
Phase 3B
Radiprodil
GRIN Therapeutics, Inc.
Phase 1/2CCC
svg103
Sovargen
Phase 1/2CC
PHYTONADIONE, (E)-(±)-
GRIN Therapeutics, Inc.
Phase 1CC

View all 12 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →